Alzheimer’s disease affects more than 30m people worldwide, mostly the elderly. After the age of 65, the chance of developing ...

II-73, has the potential to restore memory and cognitive function in a mouse model of Alzheimer's disease. The study demonstrates that the drug improves memory deficits and reverses brain cell damage, ...

The tiny protein known as transthyretin can cause big problems in the body when it misfolds after secretion. While healthy ...

COVID-19, even in mild cases, is linked to changes in Alzheimer’s disease-related brain biomarkers comparable to four years ...

A new study showed that people who took longer to enter this dream phase of sleep had higher levels of amyloid beta and tau, ...

The first participants in an international clinical trial aimed at preventing Alzheimer’s disease in young adults at high ...

Exercise may positively influence the interactions between brain cells in the hippocampus, a brain region involved in ...

Able to cross the blood-brain barrier, Xenon gas seemed to perk the mice right up, which began to become particularly active ...

For years, scientists have focused on amyloid beta buildup as the main culprit in Alzheimer’s disease, but a new study suggests the real problem might lie in a stalled protein-cutting process in the ...

The FDA has approved the sBLA for once every 4 weeks lecanemab-irmb (Leqembi®) intravenous maintenance dosing.